论文部分内容阅读
临床医师诊断心肌梗塞迄今缺乏一种明确的指标,无法客观地测量梗塞灶的大小。心肌肌凝蛋白(肌球蛋白,Mysin)及其轻链是心脏组织特有的结构蛋白,它与来自骨骼肌和平滑肌结构蛋白的抗原性不同,从而提出特异性测定和定量心肌损害的途径。应用心肌肌凝蛋白轻链可用于释放人血清中的肌凝蛋白的测定和放射性核素闪烁显影来观察心肌损害的大小和范围。本刊1982(2):38曾登载“产生抗心脏肌凝蛋白及其轻链单克隆抗体杂交瘤细胞系的建立及其初步鉴定” 的研究论文,本刊1985(2):37和1985(3):97刊登了这方面文摘和综述。为了进一步了解单克隆抗体在心血管病方面的临床应用,探讨其在心肌梗塞诊断及病理生理中的意义。特译出此文,以飧读者。
Clinicians diagnose myocardial infarction so far lack of a clear indicator of the objective measurement of infarct size. Myocardial myosin (Myosin) and its light chain are structural proteins specific to heart tissue that differ from the antigenicity of structural proteins from skeletal and smooth muscle to provide specific measures for determining and quantifying myocardial damage. The use of a cardiac myosin light chain can be used to release myosin in human serum and to detect radionuclide scintigraphy to see the magnitude and extent of myocardial damage. This issue 1982 (2): 38 has published “to produce anti-cardiac myosin and light chain monoclonal antibody hybridoma cell line established and its preliminary identification of research papers,” 1985 (2): 37 and 1985 3): 97 published abstracts and reviews in this area. In order to further understand the clinical application of monoclonal antibodies in cardiovascular disease, to explore its significance in the diagnosis of myocardial infarction and pathophysiology. Special translation of this article to readers.